Last $3.71 USD
Change Today +0.1199 / 3.34%
Volume 5.3M
GERN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:26 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

Audit Committee* - geron corp (GERN)

Name (Connections)Board RelationshipsTitleKey Developments
Karin Eastham M.D., Ph.D., CPA 82 RelationshipsIndependent Director, Chairperson of Audit Committee and Member of Nominating & Corporate Governance Committee 
V. Lawlis Jr., Ph.D. 43 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee 
Daniel Bradbury 166 RelationshipsIndependent Director and Member of Audit Committee 

Compensation Committee* - geron corp (GERN)

Name (Connections)Board RelationshipsTitle
Thomas Hofstaetter Ph.D. 18 RelationshipsIndependent Director and Member of Compensation Committee
V. Lawlis Jr., Ph.D. 43 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee
Robert Spiegel M.D., FACP 44 RelationshipsIndependent Director and Chairman of Compensation Committee
GERN Compensation vs. Industry
569.3K
361.7K
Chief Executive Officer
330.0K
267.1K
Chief Financial Officer
Share price activity for GERON CORP (GERN)
52 Week Price Performance
GERN
Industry Average

Nominating Committee* - geron corp (GERN)

Name (Connections)Board RelationshipsTitleKey Developments
Hoyoung Huh M.D., Ph.D. 111 RelationshipsChairman and Member of Nominating & Corporate Governance CommitteeGeron Corporation Announces Management Promotions
02/14/14
Karin Eastham M.D., Ph.D., CPA 82 RelationshipsIndependent Director, Chairperson of Audit Committee and Member of Nominating & Corporate Governance CommitteeGeron Corporation Announces Executive Changes
05/24/13
Susan Molineaux Ph.D. 54 RelationshipsDirector and Chairperson of Nominating & Corporate Governance CommitteeGeron Corporation Discontinues GRN1005, its Peptide-Drug Conjugate Designed to Treat Cancers in the Brain; Announces Executive Changes
12/3/12

Corporate Governance Committee* - geron corp (GERN)

Name (Connections)Board RelationshipsTitle
Karin Eastham M.D., Ph.D., CPA 82 RelationshipsIndependent Director and Member of Compensation Committee
Hoyoung Huh M.D., Ph.D. 111 RelationshipsDirector, Member of Compensation Committee and Member of Audit Committee
Susan Molineaux Ph.D. 54 RelationshipsIndependent Director and Chairman of Compensation Committee
GERN and Competitor
Insiders vs. External
Board
13%
87%
Geron Corporation
22%
78%
BioTime, Inc.
10%
90%
ReNeuron Group plc
25%
75%
Neuralstem, Inc.
13%
87%
BioRestorative Therapies, Inc.
13%
87%
IntelliCell BioSciences, Inc.
Insiders
External Board Members
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.71 USD +0.1199

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.40 USD 0.00
BioTime Inc $3.36 USD +0.05
IntelliCell BioSciences Inc $0.0002 USD 0.0001
Neuralstem Inc $2.86 USD +0.07
ReNeuron Group PLC 3.88 GBp +0.125
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 501.9x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 397.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.